FDA Approves Ravulizumab-cwvz for Neuromyelitis Optica Spect

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

Related Keywords

Japan , United States , America , Seanj Pittock , , Alexion Pharmaceuticals Inc , Mayo Clinic Center , Astrazeneca , Mayo Neuroimmunology Laboratory , Alexion Pharmaceuticals , Mayo Clinic , Multiple Sclerosis , Autoimmune Neurology , Neuroimmunology Laboratory , Safety Study , Adult Participants With , North America , Expanded Disability Status Scale Score ,